Bluejay Therapeutics has acquired Mirum Pharmaceuticals, Inc. for $820.0 million. The transaction brings Mirum's established portfolio of rare disease treatments and its late-stage pipeline under Bluejay's ownership. Mirum Pharmaceuticals is a biopharmaceutical company focused on transforming the treatment of rare diseases affecting children and adults, primarily in liver conditions. This acquisition marks a significant expansion for Bluejay Therapeutics into the rare disease therapeutic area, leveraging Mirum's commercialized products and development programs.
Mirum's portfolio includes three approved medications. LIVMARLI (maralixibat), an IBAT inhibitor, is approved for cholestatic pruritus in Alagille syndrome (globally) and PFIC (U.S., Europe). A Phase 3 EXPAND study is underway for LIVMARLI label expansion. Mirum also markets CHOLBAM (cholic acid) capsules for bile acid synthesis disorders and peroxisomal disorders, and CTEXLI (chenodiol) tablets for cerebrotendinous xanthomatosis (CTX) in adults. These products provide immediate revenue streams and established market presence in specialized rare disease segments.
Beyond its commercialized assets, Mirum brings a promising late-stage pipeline. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies: Phase 2 VISTAS for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE for primary biliary cholangitis (PBC). Volixibat has received Breakthrough Therapy Designation for cholestatic pruritus in PBC. Mirum is also planning a Phase 2 study for MRM-3379, a PDE4D inhibitor targeting Fragile X syndrome, a rare genetic neurocognitive disorder. These pipeline assets offer substantial future growth potential and diversify the combined entity's therapeutic reach.
The acquisition is strategically significant for Bluejay Therapeutics, providing immediate access to a commercial portfolio and a robust pipeline in rare diseases. The integration of Mirum's expertise in developing and commercializing treatments for rare conditions is expected to create synergies, enhancing Bluejay's market footprint and development capabilities. The combined entity is positioned to accelerate the delivery of innovative therapies to patients with high unmet medical needs, strengthening its presence in the specialized rare disease landscape.